Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

CEO Marty J Duvall interviewed in Di.TV

CEO Marty J Duvall interviewed by Di.TV

In conjunction with the FDA approval, Oncopeptides' CEO Marty J Duvall was interviewed by the Swedish economy TV channel Di.TV Börsmorgon. See the interview (after about 30 sek the interview turns into English). 

See the interview

Webcast - FDA approval

In conjunction with the FDA approval of PEPAXTO, Oncopeptides hosted a webcast Monday March 1, 2021, at 07:30 (CET), including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker, and CFO Anders Martin-Löf. The webcast was recorded. 

More information

Released

Year-end report 2020

”A year of transformation”

CEO Marty J Duvall

 

See the Webcast


For further information, please contact:

Linda Holmström
Director of Investor Relations

Profile image

Press release -

FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

Read press release
Upcoming events

Upcoming events

View calendar

Presentations

See our latest Investor presentations To the archive

Oncopeptides via e-mail

Get our latest updates straight to your inbox. Unsubscribe at anytime.

This site is protected by reCAPTCHA & the Google Privacy Policy & Terms of Service  apply.